Impact of immunopathology on the antituberculous activity of pyrazinamide
Open Access
- 17 July 2018
- journal article
- research article
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 215 (8) , 1975-1986
Abstract
In the 1970s, inclusion of pyrazinamide (PZA) in the drug regimen of tuberculosis (TB) patients for the first 2 mo achieved a drastic reduction of therapy duration. Until now, however, the mechanisms underlying PZA’s unique contribution to efficacy have remained controversial, and animal efficacy data vary across species. To understand how PZA kills bacterial populations present in critical lung lesion compartments, we first characterized a rabbit model of active TB, showing striking similarities in lesion types and fates to nonhuman primate models deemed the most appropriate surrogates of human TB. We next employed this model with lesion-centric molecular and bacteriology readouts to demonstrate that PZA exhibits potent activity against Mycobacterium tuberculosis residing in difficult-to-sterilize necrotic lesions. Our data also indicate that PZA is slow acting, suggesting that PZA administration beyond the first 2 mo may accelerate the cure. In conclusion, we provide a pharmacodynamic explanation for PZA’s treatment-shortening effect and deliver new tools to dissect the contribution of immune response versus drug at the lesion level.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (R01-AI106398, R01-AI111967)
This publication has 80 references indexed in Scilit:
- Infection Dynamics and Response to Chemotherapy in a Rabbit Model of Tuberculosis using [ 18 F]2-Fluoro-Deoxy- d -Glucose Positron Emission Tomography and Computed TomographyAntimicrobial Agents and Chemotherapy, 2012
- Sterilizing Activities of Novel Combinations Lacking First- and Second-Line Drugs in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2012
- Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infectionNature Genetics, 2011
- Dose-Dependent Activity of Pyrazinamide in Animal Models of Intracellular and Extracellular Tuberculosis InfectionsAntimicrobial Agents and Chemotherapy, 2011
- Chronic pulmonary cavitary tuberculosis in rabbits: a failed host immune responseOpen Biology, 2011
- Activity of Pyrazinamide in the Guinea Pig Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2010
- Quantitative Comparison of Active and Latent Tuberculosis in the Cynomolgus Macaque ModelInfection and Immunity, 2009
- Fast and accurate short read alignment with Burrows–Wheeler transformBioinformatics, 2009
- Enhanced Bactericidal Activity of Rifampin and/or Pyrazinamide When Combined with PA-824 in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2008
- Location of Persisting Mycobacteria in a Guinea Pig Model of Tuberculosis Revealed by R207910Antimicrobial Agents and Chemotherapy, 2007